Abstract

Objective To observe the effect and safety of the compound glycyrrhizin combined recombinant human epidermal growth factor in treatment of eczema. Methods 120 eczema patients were selected randomly divided into the treatment group (n=60) and the control group (n=60) ,the treatment group intravenously given compound glycyrrhizin once a day, 60ml combined recombinant human epidermal growth factor analgesic spray, three times a day. The control group were given intravenously compound glycyrrhizin,once a day ,60ml. Two groups of patients were continuous treatment after a month observation curative effect and adverse reaction. Results The effective rate in the treatment group(91. 67%) was higher than the control group(71.67%) ,there was significant difference(x2=6.43,P<0.05). Compared with control group, VAS of the treatment group was significantly reduced, there is significant difference (P<0.05). In the same group,within one month after treatment,before treatment and after treatment compared also has difference, there are significant difference (P<0.05). The two groups had no serious adverse reactions. Conclusion Effect of compound glycyrrhizin combined recombinant human epidermal growth factor in treatment of eczema curative was distinct,which was worth extending. Key words: Compound glycyrrhizin; Recombinant human epidermal growth factor; Eczema

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call